Table 3.
Per protocol DHAP treatment outcomes.
| Patient Age-group (HMH) | Patient Age-group (EWP) | Patient Age-group (WMH) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Treatment outcome | < 5 years (N=69) | 5-9 years (N=18) | Total (N=87) | < 5 years (N=18) | 5-9 years (N=38) | Total (N=56) | < 5 years (N=30) | 5-9 years (N=53) | Total (N=83) |
| PCR uncorrected (Day 42) | |||||||||
| ETF, n (%, 95% CI) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| LPF, n (%, 95% CI) | 0 | 0 | 0 | 1 (5.9, 0.3 – 30.8) |
1 (2.6, 0.1-15.4) |
2 (3.6, 0.6-13.6) |
6 (21.4, 9.0-41.5) |
14 (28.0, 16.7-42.7) |
20 (25.6, 16.7-37.0) |
| LCF, n (%, 95% CI) | 0 | 0 | 0 | 0 | 0 | 0 | 2 (7.1, 1.3-25.0) |
0 | 2 (2.6, 0.5-9.8) |
| ACPR, n (%, 95% CI) | 69 (100, 93.4-) | 18 (100, 78.1-) | 87 (100, 94.7-) | 16 (94.1, 69.2-99.7) |
37 (97.4, 84.6-99.9) |
53 (96.4, 86.4-99.4) |
20 (71.4, 51.1-86.1) |
36 (72, 57.3-83.3) |
56 (71.8, 60.3-81.1) |
| Total per protocol | 69 | 18 | 87 | 17 | 38 | 55 | 28 | 50 | 78 |
| Lost/withdrawn, n (%, 95% CI) | 0 | 0 | 0 | 1 (5.6, 0.3-29.4) | 0 | 1 (1.8, 0.1-10.8) | 2 (6.7, 1.2-23.5) | 3 (5.7, 1.5-16.6) | 5 (6.0, 2.2-14.1) |
| PCR corrected (Day 42) | |||||||||
| ETF, n (%, 95% CI) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| LPF, n (%, 95% CI) | 0 | 0 | 0 | 0 | 0 | 0 | 2 (9.1, 1.6-30.6) | 4 (10.0, 3.3-24.6) | 6 (9.7, 4.0-20.5) |
| LCF, n (%, 95% CI) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ACPR, n (%, 95% CI) | 69 (100, 93.4-) | 18 (100, 78.1-) | 87 (100, 94.7-) | 16 (100, 75.9-) | 37 (100, 88.3-) | 53 (100, 91.6-) | 20 (90.9, 69.4-98.4) | 36 (90.0, 75.4-96.8) | 56 (90.3, 79.5-96.0) |
| Total per protocol | 69 | 18 | 87 | 16 | 37 | 53 | 22 | 40 | 62 |
| Lost/withdrawn, n (%, 95% CI) | 0 | 0 | 0 | 2 (11.1, 1.9-36.1) | 1 (2.6, 0.1-15.4) | 3 (5.4, 1.4-15.8) | 8 (36.4, 18.0-59.2) | 13 (32.5, 19.1-49.2) | 21 (33.9, 22.7-47.1) |
HMH, Hohoe Municipal Hospital; EWP, Ewim Polyclinic; WMH, War Memorial Hospital; ETF, Early Treatment Failure; LPF, Late Parasitological Failure; LCF, Late Clinical Failure; ACPR, Adequate Clinical and Parasitological Response.